Literature DB >> 30415233

Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.

Yong Lv1, Luo Zuo1, Xuan Zhu2, Jianbo Zhao3, Hui Xue4, Zaibo Jiang5, Yuzheng Zhuge6, Chunqing Zhang7, Junhui Sun8, Pengxu Ding9, Weixin Ren10, Yingchun Li11, Kewei Zhang12, Wenguang Zhang13, Chuangye He1, Jiawei Zhong2, Qifeng Peng3, Fuquan Ma4, Junyang Luo5, Ming Zhang6, Guangchuan Wang7, Minhuang Sun11, Junjiao Dong12, Wei Bai1, Wengang Guo1, Qiuhe Wang1, Xulong Yuan1, Zhengyu Wang1, Tianlei Yu1, Bohan Luo1, Xiaomei Li1, Jie Yuan1, Na Han1, Ying Zhu1, Jing Niu1, Kai Li1, Zhanxin Yin1, Yongzhan Nie14, Daiming Fan14, Guohong Han1.   

Abstract

OBJECTIVES: Early placement of transjugular intrahepatic portosystemic shunt (TIPS) has been shown to improve survival in high-risk patients (Child-Pugh B plus active bleeding at endoscopy or Child-Pugh C 10-13) with cirrhosis and acute variceal bleeding (AVB). However, early TIPS criteria may overestimate the mortality risk in a significant proportion of patients, and the survival benefit conferred by early TIPS in such patients has been questioned. Alternative criteria have been proposed to refine the criteria used to identify candidates for early TIPS. Nevertheless, the true survival benefit provided (or not) by early TIPS compared with standard treatment in the different risk categories has not been investigated in specifically designed comparative studies.
DESIGN: We collected data on 1425 consecutive patients with cirrhosis and AVB who were admitted to 12 university hospitals in China between December 2010 and June 2016. Of these, 206 patients received early TIPS, and 1219 patients received standard treatment. The Fine and Gray competing risk regression model was used to compare the outcomes between the two groups that were stratified based on the currently available risk stratification systems after adjusting for liver disease severity and other potential confounders.
RESULTS: Overall, early TIPS was associated with an 80% relative risk reduction (RRR) in mortality at 6 weeks (adjusted HR=0.20; 95% CI: 0.10 to 044; p<0.001) and 51% RRR at 1 year (adjusted HR=0.49, 95% CI: 0.32 to 0.73; p<0.001) compared with standard treatment. In stratification analyses, the RRRs in mortality did not significantly differ among the risk categories. However, the absolute risk reductions (ARRs) of mortality were more pronounced in high-risk patients. The ARRs at 6 weeks were -2.1%, -10.2% and -32.4% in Model for End-stage Liver Disease (MELD) ≤11, 12-18 and ≥19 patients and were -1.5%, -9.1% and -23.2% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). The ARRs for mortality at 1 year were -1.7%, -5.4% and -32.7% in MELD ≤11, 12-18 and ≥19 patients, respectively, and -3.6%, -5.2% and -20.3% in Child-Pugh A, B and C patients, respectively (interaction tests, p<0.001 for both criteria). After adjusting for liver disease severity and other potential confounders, a survival benefit was observed in MELD ≥19 or Child-Pugh C patients but not in MELD ≤11 or Child-Pugh A patients. In MELD 12-18 patients, a survival benefit was observed within 6 weeks but not at 1 year. In Child-Pugh B patients, a survival benefit was observed in those with active bleeding but not those without active bleeding. However, the evaluation of active bleeding was associated with a high interobserver variability. Furthermore, early TIPS was associated with a significantly reduced incidence of failure to control bleeding or rebleeding and new or worsening ascites, without increasing the risk of overt hepatic encephalopathy.
CONCLUSIONS: Early TIPS was associated with improved survival in patients with MELD ≥19 or Child-Pugh C cirrhosis but not in patients with MELD ≤11 or Child-Pugh A cirrhosis. For MELD 12-18 or Child-Pugh B patients, future studies addressing optimal selection criteria for early TIPS remain highly warranted. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  interventional radiology; liver cirrhosis; oesophageal varices; portal hypertension; therapeutic endoscopy

Mesh:

Year:  2018        PMID: 30415233     DOI: 10.1136/gutjnl-2018-317057

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Early transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a systematic review and meta-analysis.

Authors:  Guang-Peng Zhou; Yi-Zhou Jiang; Li-Ying Sun; Zhi-Jun Zhu
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 2.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

Review 3.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

Review 4.  Recent updates in preemptive transjugular intrahepatic portosystemic shunt for acute variceal bleeding.

Authors:  James H Helzberg; Jacqueline B Henson; Andrew J Muir
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-09-26

Review 5.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 6.  Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes.

Authors:  Giuseppe Cullaro; Rajani Sharma; Jonel Trebicka; Andrés Cárdenas; Elizabeth C Verna
Journal:  Liver Transpl       Date:  2020-01-06       Impact factor: 5.799

Review 7.  Updated strategies in the management of acute variceal haemorrhage.

Authors:  Jerome Edelson; Jessica E Basso; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 3.287

8.  Impact of variceal eradication on rebleeding and prognosis in cirrhotic patients undergoing secondary prophylaxis.

Authors:  Xing Wang; Jinni Luo; Chuan Liu; Yanna Liu; Xiaoying Wu; Fengping Zheng; Zhuofu Wen; Hong Tian; Xiuqing Wei; Yunwei Guo; Jianzhong Li; Xiaoliang Chen; Jin Tao; Xiaolong Qi; Bin Wu
Journal:  Ann Transl Med       Date:  2021-04

Review 9.  Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.

Authors:  Adelina Horhat; Christophe Bureau; Dominique Thabut; Marika Rudler
Journal:  United European Gastroenterol J       Date:  2021-02-23       Impact factor: 4.623

Review 10.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.